Brief: Pasithea Therapeutics Announces Completion Of Cohort 7 In Ongoing Phase 1 Trial Of Pas-004
24/11/2025 12:27
Nov 24 (Reuters) - Pasithea Therapeutics Corp KTTA.O: PASITHEA THERAPEUTICS ANNOUNCES COMPLETION OF COHORT 7 IN ONGOING PHASE 1 TRIAL OF PAS-004 IN ADVANCED CANCER PATIENTS, WITH POSITIVE SAFETY, PHARMACOKINETIC (PK), AND PHARMACODYNAMIC (PD) DATA PASITHEA THERAPEUTICS CORP - SAFETY REVIEW COMMITTEE RECOMMENDS ESCALATION TO COHORT 8 PASITHEA THERAPEUTICS CORP -ZERO TREATMENT RELATED ADVERSE EVENTS OBSERVED DURING COHORT 7 (37MG CAPSULES) DLT PERIOD Source text: ID:nGNX5p3tj5 Further company coverage: KTTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pasithea Therapeutics
See all newsPasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings Summary
Pasithea Therapeutics Corp expected to post a loss of 16 cents a share - Earnings Preview
Brief: Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data
Brief: Pasithea Therapeutics Announces Closing Of $60 Million Public Offering Of Common Stock
Pasithea Therapeutics jumps after $60 million public offering announcement